Tags

Type your tag names separated by a space and hit enter

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Osteoporos Int. 2007 Jan; 18(1):25-34.OI

Abstract

INTRODUCTION

Randomized clinical trials have shown that risedronate and alendronate reduce fractures among women with osteoporosis. The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate.

METHODS

Using records of health service utilization from July 2002 through September 2004, we created two cohorts: women (ages 65 and over) receiving risedronate (n = 12,215) or alendronate (n = 21,615). Cox proportional hazard modeling was used to compare the annual incidence of nonvertebral fractures and of hip fractures between cohorts, adjusting for potential differences in risk factors for fractures.

RESULTS

There were 507 nonvertebral fractures and 109 hip fractures. Through one year of therapy, the incidence of nonvertebral fractures in the risedronate cohort (2.0%) was 18% lower (95% CI 2% - 32%) than in the alendronate cohort (2.3%). The incidence of hip fractures in the risedronate cohort (0.4%) was 43% lower (95% CI 13% - 63%) than in the alendronate cohort (0.6%). These results were consistent across a number of sensitivity analyses.

CONCLUSION

Patients receiving risedronate have lower rates of hip and nonvertebral fractures during their first year of therapy than patients receiving alendronate.

Authors+Show Affiliations

Cedars-Sinai Medical Center and David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90211, USA. stuarts@omcresearch.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17106785

Citation

Silverman, S L., et al. "Effectiveness of Bisphosphonates On Nonvertebral and Hip Fractures in the First Year of Therapy: the Risedronate and Alendronate (REAL) Cohort Study." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 18, no. 1, 2007, pp. 25-34.
Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007;18(1):25-34.
Silverman, S. L., Watts, N. B., Delmas, P. D., Lange, J. L., & Lindsay, R. (2007). Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 18(1), 25-34.
Silverman SL, et al. Effectiveness of Bisphosphonates On Nonvertebral and Hip Fractures in the First Year of Therapy: the Risedronate and Alendronate (REAL) Cohort Study. Osteoporos Int. 2007;18(1):25-34. PubMed PMID: 17106785.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. AU - Silverman,S L, AU - Watts,N B, AU - Delmas,P D, AU - Lange,J L, AU - Lindsay,R, Y1 - 2006/11/15/ PY - 2006/09/15/received PY - 2006/10/17/accepted PY - 2006/11/16/pubmed PY - 2007/2/24/medline PY - 2006/11/16/entrez SP - 25 EP - 34 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 18 IS - 1 N2 - INTRODUCTION: Randomized clinical trials have shown that risedronate and alendronate reduce fractures among women with osteoporosis. The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate. METHODS: Using records of health service utilization from July 2002 through September 2004, we created two cohorts: women (ages 65 and over) receiving risedronate (n = 12,215) or alendronate (n = 21,615). Cox proportional hazard modeling was used to compare the annual incidence of nonvertebral fractures and of hip fractures between cohorts, adjusting for potential differences in risk factors for fractures. RESULTS: There were 507 nonvertebral fractures and 109 hip fractures. Through one year of therapy, the incidence of nonvertebral fractures in the risedronate cohort (2.0%) was 18% lower (95% CI 2% - 32%) than in the alendronate cohort (2.3%). The incidence of hip fractures in the risedronate cohort (0.4%) was 43% lower (95% CI 13% - 63%) than in the alendronate cohort (0.6%). These results were consistent across a number of sensitivity analyses. CONCLUSION: Patients receiving risedronate have lower rates of hip and nonvertebral fractures during their first year of therapy than patients receiving alendronate. SN - 0937-941X UR - https://www.unboundmedicine.com/medline/citation/17106785/Effectiveness_of_bisphosphonates_on_nonvertebral_and_hip_fractures_in_the_first_year_of_therapy:_the_risedronate_and_alendronate__REAL__cohort_study_ L2 - https://dx.doi.org/10.1007/s00198-006-0274-z DB - PRIME DP - Unbound Medicine ER -